Merck and Johnson & Johnson (J&J) partner to produce J&J's COVID-19 vaccine; Anthony Fauci, MD, warns against shifting to a single-dose strategy for approved 2-shot vaccines; Medtronic recalls its HVAD Pump Implant Kits.
Today, President Joe Biden will announce that competitors Merck and Johnson & Johnson (J&J) will form a partnership to produce more doses of the J&J COVID-19vaccine. Reported by The Hill, the announcement follows the emergency use authorization granted by the FDA to J&J’s vaccine this past weekend that will bring 3.9 million doses into circulation this week, although no doses are set to come next week due to production delays. This is the latest of several partnerships aiming to accelerate delivery of COVID-19 vaccines, with GlaxoSmithKline having partnered with CureVac, and Sanofi and Novartis partnering with BioNTech/Pfizer.
Speaking on the possibility of administering 1 shot of the approved 2-shot COVID-19 vaccines to provide protection to more people, the nation’s top infectious disease expert Anthony Fauci, MD, said yesterday that the United States will stick to the plan of inoculating tens of millions of Americans with 2 doses. He warned that shifting to a single-dose strategy may leave people less protected and at higher risk for emerging variants. Announced yesterday, Public Health England said that 1 shot of the 2-shot vaccine manufactured by Pfizer/BioNTech was 57% to 61% effective in preventing symptomatic COVID-19 after 4 weeks in patients over the age of 70.
Medtronic announced it is recalling the HVAD Pump Implant Kit because the device may fail to initially start, restart, or have a delay in restarting after the pump has stopped, potentially causing serious patient harm, including heart attack, worsening heart failure, or death. Identified by the FDA as a Class 1 recall, the most serious type of recall, the HVAD system is used as a bridge to cardiac transplants in patients who are at risk of death from end-stage left ventricular heart failure. So far, there have been 29 complaints about the device, with 19 serious injuries and 8 life-threatening events reported.
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Strategies Needed to Address Physical Activity Before, After CVD Events
August 1st 2025Black women had lower moderate-to-vigorous intensity physical activity scores when compared with Black and White men and their White female counterparts, highlighting the need for support across patient subgroups.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Majority of Qualifying Patients Do Not Receive SGLT2i Therapy
July 24th 2025The majority of patients with heart failure who qualified for sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy did not receive treatment; a recent study aims to find out why and measure prescription trends.
Read More